38 articles
A Saudi Arabia survey reveals alarming gaps in ApoB testing knowledge among physicians and pharmacists, despite clear guideline recommendations.
A simulation of 250,000 adults finds using apoB goals to guide lipid-lowering therapy costs just $30,300 per QALY gained vs. non-HDL-C, making it highly cost-effective.
Elevated oxidized phospholipids independently predict major cardiac events after ACS, and alirocumab abolishes that risk signal.
A systematic review of 593,354 participants finds apoB consistently outperforms LDL-C and non-HDL-C for predicting cardiovascular disease risk.
Simon Hill's cardiovascular masterclass covers the Portfolio Diet, plaque regression, ApoB testing, and the sodium-potassium ratio with top experts.
A new prediction model combining APOB/APOA1 with age, diabetes, blood pressure, and inflammation markers achieves AUC of 0.796 for calcific aortic valve disease.
New review shows where fat is stored — not total body weight — determines atherogenic dyslipidemia and heart disease risk.
Discover which three blood biomarker tests offer the highest value for catching silent health risks before they become deadly.
Researcher Mike Lustgarten analyzes his latest blood panel for biological age, cardiovascular risk, and diet correlations.
The new ACC/AHA guideline introduces childhood screening, Lp(a) testing, and LDL-C treatment targets that reshape primary prevention care.
A genomic study of 3,358 biopsy-proven MASLD patients finds APOB pathogenic variants linked to significantly higher steatosis and liver injury scores.
A mass spectrometry apolipoprotein panel predicts cardiovascular events and identifies who gains the most from PCSK9 inhibitor therapy.
